company background image
CRL logo

Charles River Laboratories International NYSE:CRL Stock Report

Last Price

US$270.95

Market Cap

US$13.8b

7D

-0.9%

1Y

36.8%

Updated

28 Mar, 2024

Data

Company Financials +

Charles River Laboratories International, Inc.

NYSE:CRL Stock Report

Market Cap: US$13.8b

Charles River Laboratories International, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Charles River Laboratories International
Historical stock prices
Current Share PriceUS$270.95
52 Week HighUS$275.00
52 Week LowUS$161.65
Beta1.39
1 Month Change7.12%
3 Month Change14.62%
1 Year Change36.82%
3 Year Change-7.89%
5 Year Change88.30%
Change since IPO1,131.59%

Recent News & Updates

Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet

Mar 27
Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet

Recent updates

Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet

Mar 27
Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet

Charles River Laboratories International (NYSE:CRL) Strong Profits May Be Masking Some Underlying Issues

Feb 21
Charles River Laboratories International (NYSE:CRL) Strong Profits May Be Masking Some Underlying Issues

Charles River Laboratories: Weak Biopharma Spending Is Transitory; Initiate With 'Hold'

Feb 16

Is It Time To Consider Buying Charles River Laboratories International, Inc. (NYSE:CRL)?

Jan 17
Is It Time To Consider Buying Charles River Laboratories International, Inc. (NYSE:CRL)?

Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Not Quite Adding Up

Jan 02
Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Not Quite Adding Up

Charles River Laboratories International (NYSE:CRL) Ticks All The Boxes When It Comes To Earnings Growth

Dec 17
Charles River Laboratories International (NYSE:CRL) Ticks All The Boxes When It Comes To Earnings Growth

Charles River Laboratories: Mr. Market Went From Overvaluation To Undervaluation

Nov 26

Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 29% Discount?

Nov 12
Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 29% Discount?

Charles River: Q3 Points To Ongoing Deterioration

Nov 09

Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet

Oct 27
Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet

At US$197, Is Charles River Laboratories International, Inc. (NYSE:CRL) Worth Looking At Closely?

Oct 12
At US$197, Is Charles River Laboratories International, Inc. (NYSE:CRL) Worth Looking At Closely?

Charles River Laboratories: Diving Into The Lab (Rating Upgrade)

Oct 06

Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 27% Discount?

Aug 10
Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 27% Discount?

Charles River Laboratories: Very Attractive After The Pullback

Jul 26

Does Charles River Laboratories International (NYSE:CRL) Deserve A Spot On Your Watchlist?

Jul 22
Does Charles River Laboratories International (NYSE:CRL) Deserve A Spot On Your Watchlist?

Charles River Laboratories International (NYSE:CRL) Seems To Use Debt Quite Sensibly

Jul 03
Charles River Laboratories International (NYSE:CRL) Seems To Use Debt Quite Sensibly

When Should You Buy Charles River Laboratories International, Inc. (NYSE:CRL)?

Jun 19
When Should You Buy Charles River Laboratories International, Inc. (NYSE:CRL)?

A Look At The Intrinsic Value Of Charles River Laboratories International, Inc. (NYSE:CRL)

May 01
A Look At The Intrinsic Value Of Charles River Laboratories International, Inc. (NYSE:CRL)

Should You Be Adding Charles River Laboratories International (NYSE:CRL) To Your Watchlist Today?

Apr 16
Should You Be Adding Charles River Laboratories International (NYSE:CRL) To Your Watchlist Today?

These 4 Measures Indicate That Charles River Laboratories International (NYSE:CRL) Is Using Debt Reasonably Well

Apr 02
These 4 Measures Indicate That Charles River Laboratories International (NYSE:CRL) Is Using Debt Reasonably Well

Is Charles River Laboratories International, Inc. (NYSE:CRL) Potentially Undervalued?

Mar 19
Is Charles River Laboratories International, Inc. (NYSE:CRL) Potentially Undervalued?

Charles River gains as Guggenheim upgrades despite post-earnings selloff

Feb 23

Charles River Laboratories International: A Great Business At A Decent Price

Feb 06

Charles River acquires SAMDI Tech for $50M in cash

Jan 30

Is Charles River Laboratories International, Inc. (NYSE:CRL) Worth US$253 Based On Its Intrinsic Value?

Jan 24
Is Charles River Laboratories International, Inc. (NYSE:CRL) Worth US$253 Based On Its Intrinsic Value?

If EPS Growth Is Important To You, Charles River Laboratories International (NYSE:CRL) Presents An Opportunity

Jan 10
If EPS Growth Is Important To You, Charles River Laboratories International (NYSE:CRL) Presents An Opportunity

Charles River Laboratories sells Avian Vaccine Services business to Arlington Capital

Jan 05

We Think Charles River Laboratories International (NYSE:CRL) Can Stay On Top Of Its Debt

Dec 28
We Think Charles River Laboratories International (NYSE:CRL) Can Stay On Top Of Its Debt

Is Charles River Laboratories International, Inc. (NYSE:CRL) Potentially Undervalued?

Dec 14
Is Charles River Laboratories International, Inc. (NYSE:CRL) Potentially Undervalued?

Charles River Laboratories Non-GAAP EPS of $2.63 beats by $0.13, revenue of $989.2M beats by $18.77M, updates FY guidance

Nov 02

Charles River Laboratories: Near-Term Headwinds Outweigh Long-Term Tailwinds

Oct 18

Are Investors Undervaluing Charles River Laboratories International, Inc. (NYSE:CRL) By 21%?

Oct 18
Are Investors Undervaluing Charles River Laboratories International, Inc. (NYSE:CRL) By 21%?

Charles River Laboratories International (NYSE:CRL) Ticks All The Boxes When It Comes To Earnings Growth

Oct 04
Charles River Laboratories International (NYSE:CRL) Ticks All The Boxes When It Comes To Earnings Growth

Charles River raised to Buy at Jefferies on prospects for animal studies

Sep 30

Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet

Sep 21
Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet

Charles River Laboratories: A 'Picks And Shovels' Biomedical Play, Now Attractively Priced

Sep 10

Is Now The Time To Look At Buying Charles River Laboratories International, Inc. (NYSE:CRL)?

Sep 07
Is Now The Time To Look At Buying Charles River Laboratories International, Inc. (NYSE:CRL)?

Charles River Laboratories hits new 52-week low; shares down 43% YTD

Aug 30

Shareholder Returns

CRLUS Life SciencesUS Market
7D-0.9%-0.2%0.4%
1Y36.8%4.5%28.8%

Return vs Industry: CRL exceeded the US Life Sciences industry which returned 4.5% over the past year.

Return vs Market: CRL exceeded the US Market which returned 28.8% over the past year.

Price Volatility

Is CRL's price volatile compared to industry and market?
CRL volatility
CRL Average Weekly Movement5.1%
Life Sciences Industry Average Movement7.3%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: CRL has not had significant price volatility in the past 3 months.

Volatility Over Time: CRL's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
194721,100Jim Fosterhttps://www.criver.com

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers.

Charles River Laboratories International, Inc. Fundamentals Summary

How do Charles River Laboratories International's earnings and revenue compare to its market cap?
CRL fundamental statistics
Market capUS$13.83b
Earnings (TTM)US$474.62m
Revenue (TTM)US$4.13b

29.3x

P/E Ratio

3.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CRL income statement (TTM)
RevenueUS$4.13b
Cost of RevenueUS$2.60b
Gross ProfitUS$1.53b
Other ExpensesUS$1.05b
EarningsUS$474.62m

Last Reported Earnings

Dec 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)9.24
Gross Margin37.03%
Net Profit Margin11.49%
Debt/Equity Ratio71.7%

How did CRL perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.